Fuchs Endothelial Dystrophy Clinical Trial
Official title:
A Phase II, Interventional, Double-blind, Single-center Study of the Effects of Ripasudil on Cornea Clearing After Descemet Membrane Endothelial Keratoplasty in Subjects With Fuchs' Endothelial Corneal Dystrophy
Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and Schlemm's canal. The goal of this study is to test the potential benefits of Ripasudil therapy administered after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous corneas faster, with less post-operative complications.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02423213 -
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
|
||
| Completed |
NCT00624221 -
Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
|
N/A | |
| Completed |
NCT04051463 -
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
|
Phase 2/Phase 3 | |
| Completed |
NCT02423161 -
PIONEER: Intraoperative and Perioperative OCT Study
|
N/A |